Latest News and Press Releases

Evestia Clinical to merge with Atlantic Research Group

Data from three terminally ill cardiogenic shock patients showcase potential of procizumab to safely reverse shock within 48 hours and provide promising first-in-human evidence on the translatability...

July 14, 2025 Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX),...

In total, 11 abstracts on givinostat were accepted for presentation at the Congress, including two for an oral presentation   MILAN, Italy, July 11, 2025 – Italfarmaco S.p.A. announced...

Co-administration of OVX836 with seasonal inactivated influenza vaccine (Fluarix® Tetra) was well-tolerated and demonstrated a favorable safety profileRobust complementary immune responses were...

FDA approves Longeveron's Investigational New Drug (IND) application for stem cell therapy as a potential treatment for pediatric dilated cardiomyopathy.

Boston, July 02, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Clinical Trial Infrastructure Regional Analysis Market: Middle East and North Africa” is expected to reach...

First-in-human trial of AX-0810 will evaluate safety, tolerability, pharmacokinetics, and target engagement in healthy volunteers with initial data expected in Q4 2025Marks the first submitted...

June 25, 2025 Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”),...

Heat-triggered release mechanism unequivocally confirmedFavorable safety profile with good tolerability Signs of encouraging clinical activity in heavily pre-treated patients including meaningful...